Life Sciences

  • May 01, 2026

    Mylan Inks $11M Deal With NC Over EpiPen Pricing

    North Carolina Attorney General Jeff Jackson announced Thursday that the state has inked an $11 million settlement with EpiPen distributor Mylan Pharmaceuticals, resolving claims of anticompetitive conduct and funneling millions back into public healthcare programs.

  • April 30, 2026

    Medtronic User Says Data Hack Exposed 9M Client Records

    A Medtronic customer filed a proposed class action Thursday accusing the medical device company of failing to safeguard more than 9 million records containing personally identifiable information — including health information — exposed in a data breach earlier this month.

  • April 30, 2026

    Acadia Investors Get Final OK For $179M Deal, Atty Fees

    A Tennessee federal judge has given final approval to a $179 million settlement between investors and Acadia Healthcare Co. Inc., ending a class action that alleged the company misled investors about the strength of its U.K. operations.

  • April 30, 2026

    Jury Begins Mulling If Doctors Are Liable For Fatal Overdose

    A Philadelphia jury on Thursday began deliberations in a lawsuit accusing two doctors of enabling a 26-year-old man with chronic back pain to become hooked on opioid painkillers and fatally overdose.

  • April 30, 2026

    Trump Taps 3rd Surgeon General Pick, Drops Casey Means

    President Donald Trump nominated his third pick to be surgeon general on Thursday, withdrawing consideration for Casey Means after her confirmation stalled in the Senate. 

  • April 30, 2026

    Crypto Co. Fights Shkreli's Counterclaims In Album Case

    A cryptocurrency company suing "Pharma Bro" Martin Shkreli over ownership of a coveted Wu-Tang Clan album has asked a Brooklyn federal judge to dismiss his counterclaims, calling his claim seeking a declaration that he didn't steal trade secrets related to the album a "mirror image" of the company's claim saying he did.

  • April 30, 2026

    Supplement Industry Says FDA Wrongly Muzzled Label Claims

    A coalition of dietary supplement companies and an alternative medicine advocacy group filed suit Wednesday against the U.S. Food and Drug Administration, claiming that the agency violated First Amendment commercial speech protections when it blocked product label claims connecting certain nutrients or ingredients to health outcomes.

  • April 30, 2026

    Critical Mineral Restrictions Up 500% From 2009, OECD Says

    Global export restrictions on critical raw materials that are key for digital and renewable energy technologies increased fivefold between 2009 and 2024, which could lead to greater risks of supply chain vulnerabilities, the Organization for Economic Cooperation and Development said.

  • April 30, 2026

    NJ University Can't Escape Ex-Professor's Age Bias Suit

    A New Jersey university must face a former professor's lawsuit claiming she was demoted because she was in her 60s and fired after she complained, as a federal judge ruled her allegations were detailed enough to stay in court.

  • April 30, 2026

    Goodwin, Davis Polk Lead Avalyn's Upsized $300M IPO

    Biotechnology firm Avalyn Pharma Inc. began trading publicly Thursday after raising $300 million in an upsized initial public offering.

  • April 30, 2026

    NC Biz Court Bulletin: Corporate Raid, MV Realty Settlement

    A major case settled in the North Carolina Business Court in April as new lawsuits emerged, including a complaint by health information technology company IQVIA Holdings Inc. accusing its former top brass of orchestrating a corporate raid and defecting to a competitor. In case you missed this story and others, here are the highlights.

  • April 30, 2026

    J&J Says Ill. Ruling Backs Beasley Allen's DQ From Talc Suits

    Johnson & Johnson told a New Jersey federal court that a recent ruling in Illinois backs the Beasley Allen Law Firm's disqualification from multidistrict litigation over its talcum powder.

  • April 30, 2026

    Purdue's $125M McKinsey Deal Gets OK Ahead Of Ch. 11 Exit

    Purdue Pharma LP on Thursday secured a New York bankruptcy judge's approval of a $125 million agreement with McKinsey & Co. that settles claims tied to the consulting firm's work advising Purdue on the sale and marketing of opioids, clearing the way for the pharmaceutical company to exit Chapter 11 and put its $7.4 billion bankruptcy plan into effect.

  • April 30, 2026

    Express Scripts, Cigna Seek End To Ohio PBM Price Suit

    After the Sixth Circuit ruled that a legal dispute between Ohio and a group of pharmacy benefit managers belongs in federal court, Express Scripts and Cigna now want dismissed the lawsuit accusing them of participating in an antitrust conspiracy that is driving up prescription drug prices. 

  • April 30, 2026

    Kratom Seller Sanctioned For Deleting Blog During Suit

    A California federal judge has sanctioned Ashlynn Marketing Group Inc. in a suit alleging it hid kratom's dangerous and addictive effects, finding that it deliberately deleted a blog containing statements about kratom after the suit was filed.

  • April 29, 2026

    J&J, Neutrogena Say FDA Signed Off On Benzene Products

    Johnson & Johnson Consumer Inc. and Kenvue Inc. are calling for a permanent end to a multistate consumer lawsuit claiming their Clean & Clear and Neutrogena acne treatments degrade into the cancer-causing chemical benzene, arguing in New Jersey federal court that federal regulators have already determined that the key ingredient is safe.

  • April 29, 2026

    Feds Say Lack Of Injury Dooms Gold Card Program Challenge

    The Trump administration said a suit challenging the gold card visa program's legality must be thrown out because the immigrants and academic professionals union that filed it can't show the program hurts their chances at getting visas.

  • April 29, 2026

    High Court Seeks Path To Limited Ruling On 'Skinny Labels'

    The U.S. Supreme Court on Wednesday appeared reluctant to craft new standards for deciding whether makers of generic drugs that use so-called skinny labels have encouraged others to infringe patents, with several justices saying existing law is sufficient to make a decision.

  • April 29, 2026

    Deloitte Can't Duck Bulk Of Vax Software Theft Suit

    Deloitte must face an inventor's trade secrets misappropriation claims accusing the consulting giant of ripping off her firm's proprietary vaccination management system and securing a multimillion-dollar government contract to track the rollout of COVID-19 vaccines.

  • April 29, 2026

    Squires Snubs 10 IPRs While 4 Pass Muster In Latest Order

    U.S. Patent and Trademark Office Director John Squires rejected 10 petitions for America Invents Act patent reviews and granted four challenges in an order marking the roughly half-year mark since he took over the duty of making institution decisions.

  • April 29, 2026

    CEO Stole From His Company To Buy Mansion, SEC Says

    The former CEO of a California-based pharmaceutical company agreed Wednesday to pay the U.S. Securities and Exchange Commission $30,000 to end a lawsuit accusing him of misappropriating $3.2 million in company funds partly to buy a Beverly Hills mansion.

  • April 29, 2026

    3 Federal Circuit Clashes To Watch In May

    The Federal Circuit's May argument slate includes appeals of invalidity decisions and sanctions tied to VLSI Technology's multibillion-dollar chip patent dispute with Intel, as well as Amazon's challenge to a cloud storage patent verdict against it for over half a billion dollars.

  • April 29, 2026

    Novo Nordisk Rejects Claim It Influences GLP-1 Market

    Pharmaceutical giant Novo Nordisk told a Texas federal judge that it does not control the GLP-1 market and has not attempted to crush its competition in a bid to dismiss an antitrust suit it is facing.

  • April 29, 2026

    PBMs Say Michigan AG Price-Fixing Suit Is Unsound

    Pharmacy benefit managers Express Scripts, Evernorth Health and Prime Therapeutics have bolstered their effort to escape a federal price-fixing suit brought against them by Michigan's attorney general by arguing the statutes cited in the complaint do not apply to them.

  • April 29, 2026

    Teva Acquires Tourette's Drugmaker For Up To $900M

    Biopharmaceutical company Teva Pharmaceuticals, advised by Faegre Drinker Biddle & Reath LLP, on Wednesday announced plans to acquire Bradley Arant Boult Cummings LLP-advised Emalex Biosciences for up to $900 million.

Expert Analysis

  • FDA User Fee Talks Offer Clues On Upcoming Reforms

    Author Photo

    As the U.S. Food and Drug Administration undergoes the User Fee Act reauthorization process and renegotiates its user fee agreements over the next several months, the agency's consultation meetings with relevant industries can shed light on the FDA's priorities, and provides stakeholders an opportunity to participate in the reform process, say attorneys at Holland & Knight.

  • Moderna Case Highlights Overlooked Hurdle In Biopharma IP

    Author Photo

    The recent settlement of the patent litigation involving Moderna's COVID-19 vaccine in Delaware federal court shows that patent portfolios covering enabling platform technologies can create significant freedom-to-operate risk even when their owners are not direct competitors developing the therapeutic product, says Olga Berson at Thompson Coburn.

  • FDA Framework For Personalized Therapies Raises Questions

    Author Photo

    The U.S. Food and Drug Administration's new plausible mechanism framework for developing individualized therapies reflects the agency's focus on rare-disease drugs, but numerous significant, unresolved issues cast uncertainty on how effective the framework will be in practice, say attorneys at Ropes & Gray.

  • Emissions Permits May Not Override Pollution Exclusions

    Author Photo

    Two recent coverage rulings from the Illinois Supreme Court and the Third Circuit suggest a trend among appellate courts to deny coverage under pollution exclusions, even when the emissions happened pursuant to a government permit, say attorneys at Simpson Thacher.

  • 5 Tips For Navigating Your Firm's All-Attorney Summit

    Excerpt from Practical Guidance
    Author Photo

    Law firm retreats should be approached strategically, as they present valuable opportunities to advance both the firm's objectives and attorneys' professional development through meaningful participation, building and strengthening internal relationships, and proactive follow-up, says James Argionis at Cozen O’Connor.

  • Series

    Coaching Soccer Makes Me A Better Lawyer

    Author Photo

    Coaching youth soccer for my 7-year-old son's team has sharpened how I communicate with clients, prepare witnesses, work within teams and think about leadership, making me a more thoughtful and effective lawyer in many ways, says Joshua Holt at Smith Currie.

  • Series

    Law School's Missed Lessons: The Human Element

    Author Photo

    Law school teaches you to quickly apply intellect and logic when handling a legal issue, but every fact pattern also involves a person, making the ability to balance expertise with empathy critical to the growth of relationships with clients, colleagues and adversaries, says Rachel Adcox at Adcox Strategies.

  • Avoid The Unexpected When Drafting License Agreements

    Author Photo

    The Delaware Court of Chancery's recent decision in Commave v. Zevrain raises several practice points for attorneys drafting commercial contracts, underscoring the importance of considering anti-assignment provisions, specific exclusions and potential carveouts when drafting license agreements or other commercial contracts, say attorneys at Hogan Lovells.

  • CMS Healthcare Enforcement Initiatives May Cause Disruption

    Author Photo

    The Centers for Medicare & Medicaid Services' recently announced enforcement actions against healthcare fraud mark a significant escalation, and CMS' prior approach in the hospice sector suggests that even compliant providers and suppliers should brace for impact, say attorneys at Morgan Lewis.

  • The Benefits Of Choosing A Niche Practice In The AI Age

    Author Photo

    As artificial intelligence becomes increasingly accessible, lawyers with a niche practice may stand out as clients seek specialized judgment that automation cannot replicate, but it is important to choose a niche that is durable, engaging and a good personal fit, says Daniel Borneman at Lowenstein Sandler.

  • How PBMs Can Adapt To Plan Sponsors' Disclosure Demands

    Author Photo

    As federal reforms, growing state regulation and litigation threats push plan sponsors to expect visibility into revenue streams, pharmacy benefit managers should leverage transparency strategically, including by simplifying how they get paid, offering clients audit-ready data and co-designing contracts that are easy for fiduciaries to explain and defend, says Kristie Blase at Frazer + Blase.

  • What New Animal Welfare Enforcement Push Means For Cos.

    Author Photo

    The Trump administration's recently announced multiagency focus on violations of the Animal Welfare Act and related laws will likely lead to broader enforcement actions across industries, heightened scrutiny of compliance standards and a need for businesses to adopt effective risk management practices, says Shennie Patel at Crowell & Moring.

  • How To Engage With Gov't's Direct-To-Consumer Drug Policy

    Author Photo

    The U.S. Department of Health and Human Services' recent request for industry input on manufacturers' direct-to-consumer drug sales reflects the government's caution in this arena, and allows stakeholders a rare opportunity to help shape policy, says Mary Kohler at Kohler Health Law.

  • Series

    Podcasting Makes Me A Better Lawyer

    Author Photo

    Podcasting has changed how I ask questions and connect with people, sharpening my ability to listen without interrupting or prejudging, and bringing me closer to what law is meant to be: a human profession grounded in understanding, judgment and trust, says Donna DiMaggio Berger at Becker.

  • Patent Eligibility Bulletin: Steps To Consider As USPTO Shifts

    Author Photo

    Recent memoranda from the U.S. Patent and Trademark Office, along with some of the first patents issued under Director John Squires, indicate a recalibration of the subject matter eligibility landscape, signaling a renewed emphasis on concrete technological improvements and a potentially pro-AI stance, say attorneys at Banner Witcoff.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.